Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

EarningsnegativePrenatal TestNegative

AI Analysis

Summary

Myriad Genetics cut its 2026 revenue outlook citing weakness in prenatal testing, resulting in a 49% stock price decline. The company faces significant headwinds in its prenatal test business.

Financial Highlights

Guidance

2026 revenue outlook reduced

Outcome Details

2026 revenue outlook cut due to prenatal test weakness

Importance:7/10

Sentiment:

-0.90

guidance reductionstock declineprenatal testingrevenue weakness

Related Companies

$MYGN

Read the original article

Published by yahoo_finance on August 2, 2026 5:09 AM

Read Original